R&D News | pharmaphorum

Wednesday 9 September 2026

News

News

GSK, Merck in endometrial cancer face-off

GSK, Merck in endometrial cancer face-off

GSK and Merck & Co have both reported new clinical data with the PD-1 checkpoint inhibitors, seeking an edge in the first-line treatment of advanced endometrial cancer

News

BMS upgrades Evotec neurology alliance, now worth up to $4bn

BMS upgrades Evotec neurology alliance, now worth up to $4bn

Bristol-Myers Squibb has expanded a long-running alliance with Evotec once again, paying another $50 million upfront to deepen their collaboration on drugs to treat neurod

News

Jounce Therapeutics

Jounce elopes with Concentra, leaving Redx at the altar

A $425 million proposed marriage between Redx Pharma of the UK and Jounce Ther

News

AZ, Ionis build case for amyloidosis drug eplontersen

AZ, Ionis build case for amyloidosis drug eplontersen

Long-term data in ATTR polyneuropathy boost drug's credentials ahead of December FDA decision.

News

Kisqali pack guide

Novartis preps key early breast cancer filing for Kisqali

NATALEE trial readout sets up Kisqali as rival to Lilly's Verzenio as adjuvant treatment.

News

cancer

FDA eyes shake-up of swift approval pathway in cancer

Regulator wants more use of randomised controlled trials rather than open-label studies.